Apollo Care, LLC

Has Apollo Care, LLC received an FDA warning letter about GLP-1 drugs?

No FDA warning letter to Apollo Care, LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 11 drug recall reports for it naming semaglutide, the latest initiated Jul 29, 2026.

FDA records in this index name Apollo Care, LLC on Jul 29, 2026.

Type named in FDA records
Not stated
FDA warning letters
0
Drug recall reports
11
Drugs named
Semaglutide
Latest record
Jul 29, 2026

FDA warning letters

No FDA warning letters in this index.

Drug recalls

Record
Jul 29, 2026SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, S...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0755-2026
Jul 29, 2026SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0747-2026
Jul 29, 2026SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0748-2026
Jul 29, 2026SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, S...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0753-2026
Jul 29, 2026SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0749-2026
Jul 29, 2026SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0752-2026
Jul 29, 2026SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0757-2026
Jul 29, 2026SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0756-2026
Jul 29, 2026SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0751-2026
Jul 29, 2026SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0750-2026
Jul 29, 2026SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 10...Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass IIOngoingD-0754-2026

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Apollo Care LLC, Columbia, MO (503B)

7 listed actions, including 4 Form 483s and 2 warning letters (2019 to 2026).

Document
Jul 28, 2026Form 483483 Issued 07/28/2026fda.gov
Feb 2, 2026Warning letterWarning Letter (02/02/2026)fda.gov
Mar 27, 2025Form 483483 Issued 03/27/2025fda.gov
Nov 27, 2023Regulatory meetingRegulatory Meeting Held 11/27/2023Not linked by FDA
Apr 5, 2023Form 483483 Issued 04/05/2023FDA copy (archived)
Sep 8, 2021Form 483483 Issued 09/8/2021FDA copy (archived)
Mar 20, 2019Warning letterWarning Letter (03/20/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Apollo Care LLC, Columbia, MO.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 8 products naming semaglutide and tirzepatide under the labeler name “Apollo Care, LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (8). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.

Reporting periods
71170-495Semaglutide 12.5 mgSemaglutide 12.5 mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-640Semaglutide 1mg and Cyanocobalamin 0.5mgSemaglutide 1mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-650Semaglutide 2.5mg and Cyanocobalamin 0.5mgSemaglutide 2.5mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-690Semaglutide 12.5mg and Cyanocobalamin 2.5mgSemaglutide 12.5mg and Cyanocobalamin 2.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-811Semaglutide 2.25 mgSemaglutide 2.25 mgINJECTION, SOLUTIONSUBCUTANEOUS.9 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-821Semaglutide 6.75 mgSemaglutide 6.75 mgINJECTION, SOLUTIONSUBCUTANEOUS4.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1Compounded drugs
71170-610Tirzepatide 20mg and Pyridoxine 8mgTirzepatide 20mg and Pyridoxine 8mgINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs
71170-630Tirzepatide 60mg and Pyridoxine 12mgTirzepatide 60mg and Pyridoxine 12mgINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.